WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) View the PDF document
Table of Contents
View the documentWHO Drug Information
Open this folder and view contentsPersonal Perspectives
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsQuality Assurance Issues
Open this folder and view contentsCurrent Topics
Open this folder and view contentsGeneral Information
Close this folderRegulatory and Safety Matters*
View the documentInfliximab and congestive heart failure
View the documentInfliximab: warning of opportunistic infections
View the documentBrimonidine ophthalmic drops: accidental ingestion
View the documentP-Glycoprotein and drug interaction
View the documentNonacog alfa: intensive surveillance
View the documentTenofovir disoproxil fumarate approved for HIV infection
View the documentCiprofloxacin hydrochloride for inhalation anthrax
View the documentDTPa and limb swelling
View the documentNitrofurantoin and peripheral neuropathy
View the documentContinued suspension for tolcapone
View the documentMMR vaccine and idiopathic thrombocytopenic purpura
View the documentNew communications and networking unit at EMEA
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsRegulatory Information
View the documentRecommended International Nonproprietary Names (rec. Inn): List 46
View the documentSelected WHO Publications of Related Interest

Tenofovir disoproxil fumarate approved for HIV infection

United States of America -The Food and Drug Administration has approved Viread® (tenofovir disoproxil fumarate), a new antiviral drug indicated for treatment of HIV-1 infection in combination with other antiretroviral medicines. Tenofovir disoproxil fumarate is the first nucleotide analogue approved for HIV-1 treatment. Nucleotides are similar to nucleoside analogues, and block HIV replication in the same manner.

The introduction of potent antiviral drugs and the combined use of these drugs has markedly reduced replication of HIV in many patients and has improved survival rates. Yet because HIV mutates rapidly, resistance to one or more of these potent drugs may develop over time, necessitating the development of new drugs to treat these resistant virus strains.

FDA based its approval of tenofovir disoproxil fumarate on two clinical studies involving more than 700 patients who had previously been treated with antiretroviral agents, but showed signs of continued HIV replication despite drug therapy. Because the approval of tenofovir disoproxil fumarate was based on clinical trials involving patients who were previously treated with antiretrovirals, the risk-benefit ratio for untreated patients has yet to be determined. Furthermore, there are no study results to show long-term inhibition of the clinical progression of HIV by tenofovir.

The most frequently reported adverse events among patients in the clinical trials were mild to moderate gastrointestinal problems including diarrhea, nausea, vomiting and flatulence. Lactic acidosis and hepatomegaly with steatosis (severe liver enlargement and excess fat in the liver) have also occurred among patients treated with nucleoside analogues alone, or in combination with antiretrovirals.

Reference: FDA Talk Paper, T01-5 (2001).

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018